Lisanti Capital Growth LLC Has $890,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Lisanti Capital Growth LLC lessened its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 70.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,920 shares of the specialty pharmaceutical company's stock after selling 36,185 shares during the quarter. Lisanti Capital Growth LLC owned approximately 0.07% of ANI Pharmaceuticals worth $890,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ANIP. Innealta Capital LLC acquired a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $65,000. Ridgewood Investments LLC acquired a new position in shares of ANI Pharmaceuticals during the second quarter worth about $85,000. SG Americas Securities LLC purchased a new stake in shares of ANI Pharmaceuticals during the first quarter worth about $106,000. XTX Topco Ltd bought a new stake in ANI Pharmaceuticals in the second quarter valued at about $207,000. Finally, O Shaughnessy Asset Management LLC bought a new stake in ANI Pharmaceuticals in the first quarter valued at about $218,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ANIP. HC Wainwright restated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday. Raymond James upped their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a report on Wednesday, September 18th. Truist Financial increased their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research report on Tuesday, October 22nd. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective for the company. Finally, StockNews.com cut shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $77.33.

ANI Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ:ANIP traded down $0.74 during midday trading on Tuesday, reaching $61.00. 299,864 shares of the company were exchanged, compared to its average volume of 216,559. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The stock has a fifty day simple moving average of $58.61 and a two-hundred day simple moving average of $61.47. The firm has a market cap of $1.28 billion, a PE ratio of -112.25 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. The business had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. ANI Pharmaceuticals's revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.05 EPS. As a group, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.